Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM.

Clin Infect Dis. 2010 Mar 1;50(5):787-91. doi: 10.1086/650539.

In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .

PMID: 20121419

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.